News · Hyperfine, Inc. (HYPR) · Healthcare

Hyperfine rises 10.7% after reporting preliminary quarterly revenue and reaffirming outlook

Session of October 8, 2026 · Published October 9, 2026 · 3 min read

What happened

Hyperfine (HYPR) rose 10.7% on October 8, 2026, after it reported preliminary third-quarter revenue of approximately $6.0 million and reaffirmed full-year 2026 revenue guidance of approximately $20 to $22 million, according to a Business Wire release. The company also disclosed preliminary figures for net cash burn and for quarter-end cash and cash equivalents. The stock opened 16.6% above the previous close and finished at $0.94, with trading volume 19.6 times its 20-day average. The session was distinct from broader market action: the S&P 500 fell 0.5% while the Healthcare sector median fell 0.5%.

$0.80$0.85$0.90$0.95Aug 27Sep 8Sep 17Sep 29Oct 8HYPR closing price, last 30 sessionspromtfinance.com$0.94 (+10.7%)
Closing price over the last 30 trading sessions. On October 8, 2026, HYPR closed at $0.94, up 10.7% on the day and 11.2% higher than 30 sessions earlier.

How big was the move

The day's gain was large and mostly company-specific: the stock moved 3.5 times a typical daily move for this stock and outperformed its sector by 11.3 percentage points. Its market value was $75.3 million at the close. Trading volume that was 19.6 times its 20-day average and a strong open suggested active investor interest. Over the last five sessions the stock rose 7.8% while the S&P 500 rose 1.3%, reinforcing that company news likely drove the rally.

-10%0%+10%Jul 16Aug 13Sep 10Oct 8HYPR daily moves, last 60 sessions2 std. dev. bandpromtfinance.com
Each bar is one day's price change; the outlined bar is October 8, 2026. A typical daily move over the past year was 5.3%, so the latest move equals 2.0 times that. Moves outside the dashed lines (about 10.7%) are unusual.

In the past five years the stock had 50 sessions with a gain of at least 10.7%. Twenty trading days later the median result was a decline of 11.1%, and 14 of 50 were higher. Those historical instances provide context for how similar single-session gains have tended to perform.

The technical picture

The stock traded 14.2% above its 20-day moving average and 9.0% above its 50-day moving average, while remaining 18.3% below its 200-day moving average. The 50-day average is below the 200-day average, a sign of a weak longer-term trend. It was 57.7% below its 52-week high. The Relative Strength Index (14 days) read 65, in a neutral range between 30 and 70. Volatility was 49% annualized over 60 days, lower than 93% of its own readings over five years, implying current swings are not at the extreme end of the stock’s recent history. Over one month the stock rose 18.9%, over three months it fell 13.8% and over one year it fell 45.3%, leaving it 61.0 percentage points behind the S&P 500 for the past year.

$1.00$1.50$2.00Oct '25Jan '26Apr '26Jul '26Oct '26HYPR one-year price and moving averages200-day50-dayPricepromtfinance.com52-week high $2.2052-week low $0.77
Closing price over the past year. HYPR ends the period 57.3% below its 52-week high, above its 50-day average ($0.86) and below its 200-day average ($1.15).

Fundamentals and valuation

For the four quarters through June 30, 2026, revenue was $16.5 million, which grew 53.2% from a year earlier. Gross margin was 51.4% (a year earlier: 45.8%) and diluted earnings per share were $-0.38. The company reported operating margin of 203.3% (a year earlier: 391.1%) and free-cash-flow margin of 166.5%. Return on invested capital was 62.8% and the balance sheet showed net cash of $30.0 million. Share count over one year increased by 27.8%. Free-cash-flow yield was 36.6%.

$0.00$2M$4MQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26HYPR quarterly revenuepromtfinance.com$4M$2M$2M$3M$3M$5M$4M$4M
Quarterly revenue by period end. The latest quarter brought $4M, 44.8% more than the same quarter a year earlier.

PromtFinance sector-ranked scores place Hyperfine’s Growth at 95 (Exceptional) while Value is 23 (Very weak), Quality is 20 (Very weak), Momentum is 19 (Very weak), Revisions are 34 (Weak) and Stability is 60 (Neutral). Those scores highlight strong recent revenue growth against weaker measures of quality and momentum.

Earnings and analyst expectations

The company said it will report third-quarter 2026 financial results on November 9, 2026, and will host a conference call with management, according to the Business Wire release. Separately, the earnings-data file lists the next report as November 12, 2026. The last report, on August 6, 2026, showed earnings per share of $-0.09 against $-0.09 expected, 0.0% above estimates. Hyperfine has had 0 consecutive quarters beating estimates and an average surprise over the last four reports of 2.5% below estimates. Typical two-day reactions after recent reports have been modestly positive, with the stock rising 4.6% on average.

-$0.10-$0.05$0.00Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26HYPR quarterly earnings per sharepromtfinance.com-$0.14-$0.14-$0.12-$0.12-$0.14-$0.06-$0.09-$0.09
Diluted earnings per share by quarter. The latest quarter shows -$0.09, against -$0.12 in the same quarter a year earlier.

Five analysts provide ratings, with the consensus rated Buy and 80% of ratings at Buy; the consensus price target is $2.00, 112.7% above the closing price.

What to watch

  • November 9, 2026: company said it will report third-quarter 2026 financial results and host a conference call with management
  • November 12, 2026: next scheduled earnings report
  • Preliminary third-quarter revenue of approximately $6.0 million, as disclosed in the Business Wire release
  • Reaffirmed full-year 2026 revenue outlook of approximately $20 to $22 million
  • Preliminary figures for net cash burn and for quarter-end cash and cash equivalents for the quarter

Related stocks

More news from PromtFinance

Related stories from the last 48 hours

ASTHHealthcareOct 9Astrana Health rises after scheduling third-quarter results and conference callAstrana Health rose 4.7% after scheduling Q3 results and a conference call; the move was larger than the market and appears company-specific.Read the analysis →MRKHealthcareOct 9Merck & rises 2.3% after presenting Phase 2b/3 trial data for remigromigMerck & stock rose 2.3% as the company presented one-year BRUNELLO trial data for remigromig ahead of an October earnings report.Read the analysis →UNHHealthcareOct 8UnitedHealth falls 1.3% as investors focus on upcoming third-quarter reportUnitedHealth fell 1.3% on Oct. 8, 2026, as investors digested modest intraday weakness ahead of third-quarter results due Oct. 13 (UNH).Read the analysis →GKOSHealthcareOct 8Glaukos falls 6.3% after three-year Epioxa results and retinal licensing dealGlaukos stock fell 6.3% on October 8, 2026, after the company reported three-year results for Epioxa and struck a license deal for a retinal therapy.Read the analysis →HIMSHealthcareOct 9Hims & Hers Health rises 10.2% after class-action notices prompt investor interestHims & Hers Health stock rose 10.2% on October 9, 2026, after multiple law firms issued securities class-action notices, trading well above short-term averages.Read the analysis →PFEHealthcareOct 7Pfizer rises after FDA approves expanded use of TUKYSAPfizer rose 1.8% after the FDA approved TUKYSA as maintenance therapy for certain HER2-positive metastatic breast cancer; the move was mostly company-specific.Read the analysis →NEOGHealthcareOct 7Neogen falls 2.3% after quarterly results and FDA warning weigh on the stockNeogen fell 2.3% on October 7, 2026, after fiscal Q1 results and an FDA warning tied to a Vet product coincided with higher-than-normal volume.Read the analysis →